



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

SML/466/2011-12

Date: 09.02.2012

To,
National Stock Exchange of India Limited.
Exchange Plaza,
Plot No. C/1, G-Block,
Bandra- Kurla Complex,
Bandra (E)
Mumbai 400051.

Dear Sir,

Sub: Un-audited Financial Results.

Ref: Symbol: SHILPAMED, Series: EQ.


We are herewith enclosing Un-audited Financial Results of the Company for the quarter ended 31st December, 2011.


Kindly receive the same & acknowledge.

Thanking you,

Yours faithfully,

For SHILPA MEDICARE LIMITED


RAMAKANT INNANI
(COMPLIANCE OFFICER)



Encl: As Above.



SHILPA MEDICARE LIMITED., RAICHUR

UNAUDITED FINANCIAL RESULTS FOR 3RD QUARTER AND NINE MONTHS ENDED 31.12.2011

(Rs.in Lakhs)

Particulars	3rd Quarter Ended (Unaudited)						Nine Months Ended (Unaudited)				Previous Year Ended	
	Standalone		Consolidated				Standalone		Consolidated		Standalone	Consolidated
	31.12.2011	30.09.11	31.12.2010	31.12.2011	30.09.11	31.12.2010	31.12.2011	31.12.2010	31.12.2011	31.12.2010		
1. (a) Net Sales/Income from Operations	7335.08	6242.01	5819.12	8379.41	7123.88	6425.81	19659.79	18653.26	22335.58	20970.09	25754.35	29028.57
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	7335.08	6242.01	5819.12	8379.41	7123.88	6425.81	19659.79	18653.26	22335.58	20970.09	25754.35	29028.57
2. Expenditure												
a. Increase/(Decrease) in stock in trade and WIP	634.95	(1450.91)	(98.06)	670.71	(1528.64)	(57.84)	(2047.96)	(45.66)	(2143.14)	69.90	883.98	933.79
b. Consumption of raw materials	3782.47	5134.99	3761.18	4074.67	5500.59	3915.52	13754.25	10987.48	14553.59	11633.69	14242.30	15111.33
c. Purchase of traded goods	358.88	51.60	71.35	358.88	51.60	71.35	481.64	124.33	481.64	124.33	299.99	299.99
d. Employees cost	557.38	555.01	428.83	999.99	994.76	796.66	1581.35	1318.41	2865.18	2427.94	1758.52	3312.38
e. Exchange - (Gain) / Loss	395.06	146.06	(124.43)	397.39	153.29	(121.81)	492.82	(371.66)	499.04	(369.24)	(378.44)	(379.96)
f. Depreciation	293.15	283.39	267.48	375.15	355.98	336.08	847.92	778.68	1072.02	980.95	1042.11	1297.79
g. Other expenditure	583.08	613.39	407.60	802.64	786.01	568.77	1599.82	1109.31	2174.19	1567.09	1668.75	2349.80
h. Total	6604.97	5333.53	4713.95	7679.43	6313.59	5508.73	16709.84	13900.89	19502.52	16434.66	19517.21	22925.12
3. Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	730.11	908.48	1105.17	699.98	810.29	917.08	2949.95	4752.37	2833.06	4535.43	6237.14	6103.45
4. Other Income	243.51	267.29	150.58	172.00	186.26	158.02	789.68	215.22	638.11	226.43	423.58	407.58
5. Profit before Interest and Exceptional Items (3+4)	973.62	1175.77	1255.75	871.98	996.55	1075.10	3739.63	4967.59	3471.17	4761.86	6660.72	6511.03
6. Interest	46.76	38.49	34.61	50.91	38.18	39.80	113.08	158.74	123.56	172.45	184.75	206.01
7. Profit after Interest but before Exceptional Items (5-6)	926.86	1137.28	1221.14	821.07	958.37	1035.30	3626.55	4808.85	3347.61	4589.41	6475.97	6305.02
8. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	107.67	0.00	107.67	107.67	107.67
9. Profit from Ordinary Activities before tax (7+8)	926.86	1137.28	1221.14	821.07	958.37	1035.30	3626.55	4916.52	3347.61	4697.08	6583.64	6412.69
10. Tax expense	166.40	227.01	182.71	173.33	200.01	182.98	884.53	1209.04	864.74	1209.56	1491.11	1460.00
11 Profit after tax 'from Ordinary Activities after tax (9-10)	760.46	910.27	1038.43	647.74	758.36	852.32	2742.02	3707.48	2482.87	3487.52	5092.53	4952.69
12. Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit for the period (11-12)	760.46	910.27	1038.43	647.74	758.36	852.32	2742.02	3707.48	2482.87	3487.52	5092.53	4952.69
14. a) Add: (Gain) / loss Pertaining to Minority interest	0.00	0.00	0.00	(6.38)	6.42	0.00	0.00	0.00	0.04	0.00	0.00	0.09
b) Less: Share in losses of Associates to the extent of Investment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.00
15 Net Profit / (loss) after Minority Interest	760.46	910.27	1038.43	641.36	764.78	852.32	2742.02	3707.48	2482.91	3487.52	5092.53	4942.78
16. Paid-up equity share capital (Face value of Rs 2/-)	480.48	480.48	480.48	480.48	480.48	480.48	480.48	480.48	480.48	480.48	480.48	480.48
17. Reserves excluding Revaluation Reserves as per previous year B/S.	-	-	-	-	-	-	-	-	-	-	22603.09	21240.49
18. Earnings Per Share (EPS)-Face Value of Rs 2/-												
a) Basic EPS before Extraordinary items	3.17	3.79	4.32	2.67	3.18	3.55	11.41	16.54	10.34	15.56	22.08	21.48
b) Basic diluted EPS after Extraordinary items	3.10	3.71	4.23	2.62	3.12	3.48	11.18	16.18	10.12	15.22	21.84	21.24
19. Public Shareholding	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724	10819724
- Percentage of shareholding	45.04	45.04	45.04	45.04	45.04	45.04	45.04	45.04	45.04	45.04	45.04	45.04
20. Promoters & Promoters group Shareholding												
a) Pledged / Encumbered	-	-	-	-	-	-	-	-	-	-	-	-
b) Non encumbered	13204441	13204441	13204441	13204441	13204441	13204441	13204441	13204441	13204441	13204441	13204441	13204441
% of shareholding of promoters & promoter group	100	100	100	100	100	100	100	100	100	100	100	100
% of total Share Capital of the Company	54.96	54.96	54.96	54.96	54.96	54.96	54.96	54.96	54.96	54.96	54.96	54.96

Notes

- The above results is reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company and have undergone "Limited Review" by the Statutory Auditors of the Company.
- Previous quarter / year's figure are regrouped wherever necessary.
- Shareholders complaints outstanding at the beginning of the quarter- Nil, received-11 and resolved during the quarter-11 and pending Nil.
- As per As-17 reportable segment is only one i.e Bulk Drug & API, therefore, segment reporting is not applicable
- From 07.09.2011 Nu-Therapeutics Pvt Ltd has become subsidiary of the Company.

Place: Vizag

Date: 09/02/2012

By the order of the Board of Directors

M/S. SHILPA MEDICARE LIMITED RAICHUR

Omprakash Manu

Chairman

